Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Oct 2018
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Effectiveness of vedolizumab in real world clinical practice is unknown. ⋯ Over 60% of IBD patients respond to vedolizumab. Many patients discontinue treatment over time. CD and disease burden impair both short- and long-term response. Vedolizumab seems to be safe in clinical practice.